Grace Therapeutics Inc.
Organization details
- Legal name
- Grace Therapeutics Inc.
- Former names
- Acasti Pharma Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- Canada
- Fiscal year end
- March
- Ticker symbol
- GRCE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001444192
Board of directors
-
A. Brian Davis · DirectorSince 2023
-
Donald Olds · DirectorSince 2023
-
Edward Neugeboren · DirectorSince 2023
-
George Kottayil · DirectorSince 2023
-
Michael Derby · DirectorSince 2023
-
Prashant Kohli · Director · Chief Executive OfficerSince 2023
-
Vimal Kavuru · DirectorSince 2023
Chief executives
Director election results
Annual meeting of September 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.4%
-
99.5%
-
99.6%
-
99.6%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Matinas Biopharma Holdings Inc. Same sectorvia Edward Neugeboren
-
Retension Pharmaceuticals Inc. Same sectorvia Donald Olds
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $807,576
- 22 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +3,087 | $1.77 | $5,478 |
| Nov 4, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +5,027 | $1.80 | $9,060 |
| Nov 3, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +10,328 | $1.79 | $18,481 |
| Oct 26, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +66,411 | $1.77 | $117,408 |
| Oct 22, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +21,390 | $1.93 | $41,193 |
| Oct 19, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +4,256 | $1.88 | $8,001 |
| Oct 16, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +36,347 | $1.89 | $68,758 |
| Oct 15, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +23,485 | $1.95 | $45,685 |
| Oct 14, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +11,233 | $1.93 | $21,735 |
| Oct 12, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +7,215 | $2.02 | $14,574 |
| Oct 9, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +5,340 | $2.04 | $10,918 |
| Oct 8, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +2,077 | $2.02 | $4,190 |
| Oct 5, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +1,694 | $2.06 | $3,490 |
| Oct 2, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +20,000 | $2.07 | $41,368 |
| Oct 1, 2026 | Opaleye Management Inc. 10% owner | Open-market purchase | +38,796 | $2.04 | $78,962 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Grace Therapeutics Inc.
Who is the CEO of Grace Therapeutics Inc.?
Prashant Kohli is Grace Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Grace Therapeutics Inc.'s board?
Grace Therapeutics Inc.'s board has 7 directors: A. Brian Davis, Donald Olds, Edward Neugeboren, George Kottayil, Michael Derby, Prashant Kohli and Vimal Kavuru.
Are Grace Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Grace Therapeutics Inc. insiders bought $807,576 of shares in 22 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="grace-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.